Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Vertex Pharmaceuticals (0QZU) Share Price & Analysis

9 Followers

0QZU Stock Chart & Stats

$544.69$1.46(0.27%)
At close: 4:30 PM GMT
$500$525$550Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$538.00 - $559.46
52-Week Range
$410.40 - $579.00
Previous Close
$543.23
Volume
N/A
Average Volume (3M)
865
Market Cap
$138.69B
Enterprise Value
$133.59B
Total Cash (Recent Filing)
$6.30B
Total Debt (Recent Filing)
$6.48B
Price to Earnings (P/E)
34.8
Beta
0.72
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
4.2
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

CF Franchise Growth

The CF franchise continues to produce recurring demand while ALYFTREK expands treatment coverage and international access. Ongoing patient uptake, label expansion, and reimbursement progress support durable revenue generation from Vertex’s established commercial foundation.

Commercial Diversification

Growth beyond CF is becoming commercially meaningful, reducing reliance on a single franchise over time. Progress across gene therapy, pain treatment, and endocrinology creates multiple potential revenue streams and supports broader long-term earnings durability.

Profitability And Liquidity

Very high margins, strong quarterly profitability, and substantial liquidity give Vertex resources to fund research, launches, and business development. This financial capacity supports resilience and allows continued investment while newer products scale commercially.

Bears Say

Higher Acquisition Leverage

The Crinetics financing materially increased debt and adds recurring interest obligations to the cost base. Although Vertex retains substantial cash generation, higher leverage reduces balance-sheet conservatism and makes sustained operating execution more important.

Rising Operating Costs

Higher spending can support launches and pipeline development, but it also raises the earnings hurdle for Vertex’s expanding portfolio. Acquisition-related costs and integration spending may constrain margin progression until commercial growth generates sufficient operating leverage.

Softening Cash Conversion

Vertex still generates substantial cash, but weaker recent free-cash-flow momentum and conversion indicate less efficient translation of reported earnings into liquidity. If sustained, this could limit flexibility for investment, acquisitions, debt reduction, or shareholder returns.

Vertex Pharmaceuticals News

0QZU FAQ

What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest share price was $410.40 and its highest was $579.00 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $138.69B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 88 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Nov 02, 2026. The company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.817 by -$0.057.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.20.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 253,537,670 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.76 in its last earnings report, missing expectations of $4.817. Following the earnings report the stock price went down -4.002%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Hedge funds hold Vertex Pharmaceuticals shares: the largest hedge-fund position in Vertex Pharmaceuticals is 1,793,687,036 shares, and hedge funds decreased their holdings by 212.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology